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The variety of recombinant protein expression systems have been developed as a resource of FVII gene expression. In the current
study, the authors used a novel protein expression system based on the Iranian Lizard Leishmania, a trypanosomatid protozoan as
a host for expression of FVII. Plasmid containing cDNA encoding full-length human FVII was introduced into Lizard Leishmania
and positive transfectants were analyzed by SDS-PAGE and Western blot analysis. Furthermore, biological activity of puriﬁed
protein was detected by PT assay. The recombinant strain harboring a construct was analyzed for expression of FVII at the mRNA
and protein level. Puriﬁed rFVII was obtained and in order to conﬁrm the puriﬁed compound was in fact rFVII. Western blot
analysis was carried out. Clotting time in PT assay was reduced about 30 seconds with the puriﬁed rFVII. In Conclusion, this study
has demonstrated, for the ﬁrst time, that Leishmania cells can be used as an expression system for producing recombinant FVII.
1.Introduction
FVIIisavitamin-K-dependentserineproteasesynthesizedin
the liver and plays an important role in blood coagulation
[1] .T h eg e n ef o rh u m a nF V I I( N G009262.1) is located
on chromosome 13 (13q34); it has approximately 14kb
and consists of nine exons and eight introns. Alternative
splicing patterns of the gene mRNA transcripts result in
2 coagulation factor VII isoforms, “a” and “b” precursors.
Isoform “b” (NM 019616.2) is the prevailing form in normal
liver; it does not include exon 1b and thus encodes a shorter
signal peptide than isoform “a” (NM 000131.3). The mature
protein encoded by the two transcript variants is identical
withasingle-chainpeptidewith406aminoacidresiduesand
molecular mass of approximately 50KDa [2].
Upon activation, FVII is converted to the protease FVIIa,
and a peptide bond between Arg152 and Ile 153 is separated.
So, the light chain, consisting of a γ-carboxyglutamic-acid
containing (Gla) domain and two epidermal growth-factor-
like (EGF) domains, is covalently connected to the heavy
chain (the serine protease domain) through a single disulﬁde
bond [3] (Figure 1).
Based on the understanding of the role of activated
FVII in the treatment of the coagulation disorders, synthesis
of recombinant activated FVII (rFVIIa) was considered.
A review of application of rFVIIa (Novo Seven) over the
past two decades indicates that initially this compound was
approved for use in patients with congenital or acquired
hemophilia who produce inhibiting antibodies toward factor
VIII or IX. By this approach, high concentrations of FVIIa,
which are achieved by pharmacological doses of rFVIIa,
bind to preactivated platelets. Through this approach, it can
bypass the need for VIIIa and IXa as a result of activation
of FX to FXa. This would result in an increased generation2 Journal of Biomedicine and Biotechnology
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Figure 1: Human coagulation factor VII. FVII is a serine protease of 406 residues. Diﬀerent domains of FVII are shown. Posttranslational
modiﬁcations of the FVII molecule include (1) γ-carboxylation of 10 glutamic acid residues in the N-terminal part of the molecule,
(2) N-glycosylation of asparagine residues in positions 145 and 322, and (3) O-glycosylation of serine residues 52 and 60. , gamma-
carboxyglutamic acid; , O-glycosylation sites; , N-glycosylation sites; Arg152 and Ile153, cleavage site generated after activation; ,
joining of two chains of FVIIa by a single disulﬁde bond between cys135 and cys262.
of thrombin which produces a tight, well-structured ﬁbrin
haemostatic plug, which is resistant to ﬁbrinolysis [4–6].
Also, it is reported in the literature that the recombinant
factor VIIa has been used eﬀectively in patients with other
categories of coagulation defects or patients with normal
coagulation system who, for instance, experience excessive
bleeding, as a result of trauma or surgery. However, it
should be mentioned that adverse events such as arterial
thromboembolism have been reported among patients who
received rFVIIa, particularly among those who were 65 years
of age or older [7–9].
Initially, BHK cells and subsequently the variety of
recombinant protein expression systems such as insect and
mammalian cells have been developed as a resource of FVII
gene expression [4, 10, 11].
Using mammalian systems has a number of drawbacks:
(a) high price of cell-culture media, (b) possibility of
contamination of products with viruses and prions depend-
ing on the components of animal origin, and (c) high
puriﬁcation cost [12, 13].
Recently, a novel protein expression system was intro-
duced which was based on the nonpathogenic trypanoso-
matid ﬂagellate Leishmania tarentolae, a protozoan parasite
of lizards [14].
The main advantages of Leishmania expression system
a r ea sf o l l o w s :
(1) easy to handle like E. coli and yeast expression
systems,
(2) full eukaryotic protein folding,
(3) The mammalian-type posttranslational modiﬁcation
of target proteins and cultivation in low-cost media,
(4) high speciﬁc growth rate in comparison to mam-
malian cells [15, 16].
In the present study, attempt is made to express heterolo-
gous recombinant human FVII (rFVII) by the Iranian Lizard
Leishmania (I.L.L.) Expression System [17].
2.MaterialsandMethods
2.1. Cell Line, Hosts, and Plasmid. Human hepatoma HepG2
cell line [18] was obtained from the National Cell Bank of
Iran (ncbi code: c158). It was grown in RPMI1640 (Gibco,
52400: U.K.) medium at 37◦Ci n5 %C O 2 supplemented
with (a) 10% fetal bovine serum, (b) 1μg/mL vitamin K1,
(c) 100u/mL penicillin and) (d)100μg/mL streptomycin
(GIBCO, Pen-Strep,15140). The E. coli Top10 strain, the
bacterial host, was cultured in LB broth medium. pLEXSY-
hyg2 plasmid was prepared from Jena Bioscience company of
Germany.
2.2. Preparation of FVII cDNA. Total RNA was extracted
using a commercial kit (QIAGEN RNeasy Mini Kit, Ger-
many) from the hepG2 cell line. The synthesis of the FVII
encoding cDNA was performed by using SuperScript III
reverse transcriptase (Invitrogen, USA). RT reaction was
c a r r i e do u ta t2 5 ◦C for 10min, 55◦C for 50mins and 85◦C
for 5min using random hexamer.
The PCR program consisted of an initial denaturation
at 94◦Cf o r5m i n u t e s .At o t a lo f3 5c y c l e sw a sc a r r i e d
out comprising of the following steps: 94◦Cf o r3 0 s ,
60◦C for 60s, 72◦C for 60s, followed by 72◦Cf o r 5m i n
as a ﬁnal extension using the forward primer 5 CTCG-
AGATGGTCTCCCAGGCCCTCAG3  and reverse primer
5 GCGGCCGCCTAGGGAAATGGGGCTCGCAG3 .
2.3. Plasmid Construction and Conﬁrmation of the Pre-
pared Construct. The puriﬁed PCR product of transcript
isoform “a” was ligated to pTZ57R/T vector [19]a n d
transformed in E. coli TOP10 strain competent cell as
de-scribed previously [20]. The presence and accuracy of
the insert was conﬁrmed by restriction analysis and hem-
inested PCR using two pairs of internal primers, for-
ward primer 5 ATGGTCTCCCAGGCCCTCAG3  and re-
verse primer 5 AGATGGTGTTGATCAGGGTCC3  ﬂanking
a 700bp fragment inside the gene, and ﬁnal veriﬁcation was
carried out using DNA sequencing.
The cloned FVII gene was digested by NotI and SlaI
restriction enzymes (Fermentas, Lithuania) and cloned into
pLEXSY-hyg2 plasmid (EGE-232, Jena Bioscience, Jena,Journal of Biomedicine and Biotechnology 3
Germany).The presence and correct orientation of the insert
was analyzed by PCR and NotI and SlaI restriction enzymes.
2.4. Transfection and Cultivation Condition of Lizard Leish-
mania. I.L.L. [17] was cultivated in RPMI1640 (Gibco-
BRL, Eggenstein, Germany) medium supplemented with
10% fetal bovine serum,100u/mL penicillin and 100μg/mL
streptomycin (GIBCO, Pen-Strep, 15140), at 25◦C, 15μg/mL
haemin (Sigma, St. Louis, Mo, USA). Plasmid containing
cDNA encoding human FVII was linearized with SwaI
(BIORON, Germany) [14] and used for transfection of
the I.L.L. by electroporation in 4mm cuvettes using an
electroporator (Bio-Rad Gene Pulser) [21]. After two pulses,
stable transfectants were selected on solidiﬁed RPMI media
containing 25μg/mL hygromycin B (Sigma, St. Louis,
Mo, USA) [22]. For transcription and expression assays,
recombinant I.L.L were cultured in RPMI-based suspension
supplemented with haemin (5μg/mL), penicillin (50U/mL),
and streptomycin (50μg/mL) at 26◦C in the absence of light
and under shaking condition (140rpm) [22, 23].
2.5. Expression and Puriﬁcation of Recombinant FVII. The
expression of rFVII was assayed by RT-PCR reaction on
extracted total RNA of approximately 108 recombinant
Leishmania cells. Ampliﬁcations of 1400bp of the FVII
fragment were carried out by speciﬁc primers. Furthermore,
the expression of rFVII protein in Leishmania was conﬁrmed
by SDS-PAGE and western blotting procedure.
To select positive transfectants of I.L.L., cells were har-
vested by centrifugation at 3000rpm for 15min and washed
in PBS. The pellets were immediately lysed in 2x SDS-
PAGE sample buﬀer (100mMTris-HCl pH 8, 20% glycerol,
4% SDS, 2% beta mercaptoethanol, 0.2% bromophenol
blue) then boiled for 5 minutes. Samples were loaded on a
12% SDS-PAGE. The gel was stained by Coomassie brilliant
blue R250, and gene expression was analyzed. The same
procedures were carried out on the control sample in parallel
for comparison.
For Western blot analysis, cell lysate was separated on
12% SDS-PAGE and electrophoretically transferred onto
pvdf membrane. After UV crosslinking for protein ﬁxa-
tion, the membrane was blocked with 3% BSA at room
temperature. The speciﬁc factor VII polyclonal antibody,
HRP-conjugated (US Biological, F0015-20B) was used in
1:500 dilutions. The protein band was detected by DAB
(Diaminobenzoic Acid) and H2O2.
After selecting the appropriate clone and cell growth,
cell pellet from 10mL shake ﬂask culture was obtained with
centrifuge in 3000rpm for 10min and then resuspended in
5mM Tris-HCl, pH 8.2. The suspension was immediately
sonicated twice for 20s. Then, cell lysate was applied to
an aﬃnity column containing speciﬁc factor VII polyclonal
antibody coupled to CNBr-activated sepharose 4B resin
(Amersham Biosciences, Sweden). According to the manu-
facturer’s instructions, rFVII was eluted with the changes in
pHandbyusing0.1Mglycine,withtheﬁnalpHof2.8.Then,
acetone precipitation of adsorbed rFVII was performed. The
precipitated product was resuspended in 1x TBS, and dot
blot analysis was carried out by spotting the suspension
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Figure 2: (a) FVII-PCR product, Lanes (1, 2, 3), 100bp DNA
ladder(4)(b)RestrictionanalysisofPCRproduct.Lane1:digestion
with HphI that revealed a 700bp fragment, Lane 2: PCR product
without enzyme eﬀect. (c) Lane 1: 700-bp PCR product obtained
by heminested PCR.
o n t oap v d fm e m b r a n e .T h es p e c i ﬁ cf a c t o rV I Ip o l y c l o n a l
antibody was allowed to bind, and positive-colored spot was
detected.
Subsequently, the glycine buﬀer composition of eluted
rFVII was exchanged by 0.1Mimidazole, NaCl 0.2M, pH 7.3
buﬀer through the dialysis.
After Dialysis, soluble protein was further characterized
by SDS-PAGE and western blot analysis, which was per-
formed as mentioned above. Also, puriﬁed rFVII concen-
tration was determined spectrophotometrically by Biopho-
tometer (Eppendorf, Germany) at 280nm.
2.6. Analysis of Puriﬁed rFVII. For determination of coagu-
lant activity of puriﬁed rFVII, clotting times of the dialyzed
rFVII were obtained by a one stage clotting assay (PT-
based assay for FVII). Hence, PT assay was performed
based on human plasma immunodepleted of factor VII
(DiagnosticaStago,France)incombinationofpuriﬁedrFVII
and human thromboplastin-D (Thermo Scientiﬁc, USA).
The coagulation was initiated by addition of PT reagent,
and the coagulation time was recorded and compared with
that of FVII (FVIIa, US Biological), as a positive control and
puriﬁed sample obtained from untransfected I.L.L. (negative
control), using ﬁbrin timer cups and a semiautomated
coagulation analyzer (Option 4 plus Biomerieux, Germany).
A standard curve was made, by using dilutions of (1/1),
(1/2), (1/5), (1/10), (1/20), (1/40) of Unicalibrator (Stago,
Ref. 00625) that related to deﬁned 100%, 50%, 20%, 10%,
5%, and 2.5% of FVIIa levels, respectively. Also, several
dilutions of dialyzed protein were made. An aliquot (100μL)4 Journal of Biomedicine and Biotechnology
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Figure 3: Construction of expression plasmid containing human FVII (pLexsy-hFVII). Map of pLEXSY-2 vector and the strategy used for
plasmid construction are shown. The cDNA sequence encoding human FVII was inserted in corresponding restriction sites SlaI and NotI.
More information about the vector itself can be found on http://www.jenabioscience.com/, pLEXSY-hyg2 (EGE-232).
ofeachdilutedsamplewasaddedto100μLofhumanplasma
immunodepletedoffactorVII;200μLofthromboplastinwas
added and the clotting time was recorded immediately [24].
All determinations were carried out in duplicate and were
compared to the standard curve. Hence, speciﬁc activity of
the puriﬁed rFVII was determined.
3. Results
3.1. FVII Fragments Preparation and Its Conﬁrmation. Spe-
ciﬁc primers were used for the isolation of full-length
rFVII, and the amplicon with expected size (about 1400-
bp) was produced (Figure 2(a)). In order to conﬁrm the
correctness of the amplicon, puriﬁed PCR product was
digested with HphI which resulted in two fragments of 700-
bp (Figure 2(b)).
3.2. Construction of the Recombinant pLEXSY-hyg2-FVII
Plasmid. To generate pTZ57r-FVII, the PCR product was
cloned into pTZ57r vector. The accuracy of the gene was
determined by heminested PCR approach which yielded
the speciﬁc 700-bp ampliﬁed product (Figure 2(c)), and by
KpnI enzyme digestion which revealed a 1200-bp fragment.
Additional conﬁrmation was obtained by DNA sequencing.
Subsequently, the resultant pTZ57r-FVII was digested
with SlaI and NotI restriction enzymes. In order to generate
pLexsy-hFVII construct, the correct fragment was inserted
into the corresponding restriction sites of pLEXSY-hyg2
expression vector (Figure 3).
3.3. Expression and Puriﬁcation of Recombinant Human FVII
in I.L.L. Cells. Approximately 5μg pLEXSY-hyg2-FVII plas-
mid was linearized by SwaI restriction enzyme (Figure 4(a)).
It was transfected into I.L.L. cells by electroporation, and
stable transfectants were selected by culturing cells on
solid medium with hygromycin. Subsequently, two to three
passages in liquid medium containing hygromycin were
performed, and the recombinant promastigotes harboring a
construct was analyzed for expression of rFVII.
In order to verify rFVII mRNA synthesis in the host,
RT-PCR was performed on total RNA extracted from
transformed cells using FVII primers. The desired band with
the expected size of 1400bp was obtained (Figure 4(b)).
Furthermore, the expression of rFVII in Leishmania cells
was determined by SDS-PAGE, and western blot analyses.
Expressed protein was run onto 12% (V/V) SDS-PAGE
and the protein band about 55KD was detected which
indicatesproteinexpressionofrFVIIasshowninFigure5(a).Journal of Biomedicine and Biotechnology 5
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Figure 4: (a) Linearized pLEXSY-hyg2-FVII construct with SwaI (Lanes 1, 2), control plasmid (Lane 3). The arrow head shows a 6500-bp
fragment containing cDNA sequence encoding human FVII, hygromycin B resistance gene, 5  and 3  portion of the small subunit of L.
tarentolaer RNA gene (5  and 3  ssu) and three UTRs: utr1, utr2, and utr3. (b) Conﬁrmation of FVII expression by transfected Leishmania
cells Lanes (1, 2), Control cells (Lanes 3, 4), Control plasmid (Lane 5).
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Figure 5: Analysis of expression of the human FVII by SDS-PAGE and western blotting and detection of puriﬁed rFVII by dot blot and western
blot. (a) FVII protein band on 12% SDS-PAGE from transfected (Lanes 2, 3) and untransfected I.L.L. as a negative control (Lane 4). (b).
expressed FVII protein band in transfected I.L.L. (Lane 2) and negative control untransfected cells (Lane 1), commercially available rFVII as
a positive control (Lane 3). (c) Positive control sample rFVIIa (Lane 1), puriﬁed rFVII appears as a brown colored spot (Lane 2), puriﬁed
product of negative control untransfected cells. (d) the puriﬁed rFVII from transfected I.L.L (Lane 2, 3) was analyzed by western blot. Two
chains of activated form of rFVII with corresponding length are shown; Lane 1, untransfected I.L.L.
The protein identity was veriﬁed by western blot analysis.
The assay revealed speciﬁcally recognition of rFVII coding
gene by human FVII antibody (a sheep polyclonal antibody
to human FVII, IgG HRP-conjugated). The results were
compared with the positive control sample FVII (FVIIa, US
Biological), and no reactivity was observed with negative
control cells (Figure 5(b)).
Puriﬁcation of rFVII was achieved using aﬃnity column
and by passing a cell lysate of Leishmania over aCNBr-
activated sepharose 4B resin coupled to speciﬁc factor
VII polyclonal antibody. The presence of puriﬁed rFVII
was conﬁrmed by visualizing a brown spot in a dot blot
membraneagainstspeciﬁcpolyclonalantibody(Figure5(c)).
Furthermore, western blot analysis of the puriﬁed rFVII
revealed that, during puriﬁcation, it was converted into the
two-chain-activated form (Figure 5(d)).
Theresultingtwochainswerelightandheavychainswith
am o l e c u l a rw e i g h to f∼20KDa and ∼30KDa, respectively.
The puriﬁed rFVII concentration was estimated to be about
10μg per 10mL of culture medium.
Dialyzed rFVII was added to human plasma immunode-
pleted of factor VII, and coagulation times were determined.
The biological activity of dialyzed rFVII from I.L.L. in
comparisonwithFVII(FVIIa,USBiological)wasperformed.
In the initial experiments, a reduction in clotting time of
about (33 ±3) seconds with the puriﬁed rFVII was observed
(Figure 6).
Also, comparison between diﬀerent dilutions of dialyzed
rFVII in a similar assay with standard curve indicated
that dialyzed rFVII (rFVIIa) at dilution of (1/1) retained
approximately 9% of the activity of Unicalibrator with 100%
FVIIa level (Figure 7).
4. Discussion
In recent years, there has been increasing interest in the
use of recombinant activated factor VII (rFVIIa) as an
adjunct to the coagulation process. rFVIIa is a useful
treatment option for patients with congenital or acquired
hemophilia. The ﬁndings represent signiﬁcant advancement6 Journal of Biomedicine and Biotechnology
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Figure 6: Prothrombin time assay. PT assay was performed for
determination of coagulant activity of dialyzed rFVII. Coagulation
time measured for dialyzed rFVII produced from transfected I.L.L.
(C1: clone 1), commercially available rFVIIa as a positive control
(p.c.), puriﬁed sample obtained from untransfected I.L.L. as a
negativecontrol(n.c.).Areductioninclottingtimeofabout(33±3)
seconds with the puriﬁed rFVII was observed. Data are shown as
mean±SD.
in the management of patients who produce antibodies
against FVIII or FIX [7].
Initially, BHK cells and subsequently the variety of
recombinant protein expression systems such as insect and
other mammalian cells have been developed as a resource
of FVII gene expression [4, 10, 11]. However, in this study,
leishmania expression system was used as a host cell.
I.L.L.cellsweretransfectedwiththevectorpLexsy-hFVII,
which encoded a full-length recombinant human FVII of
406 amino acids, and was integrated properly between 5 
and 3  portion of the small subunit of rRNA gene and
powerfully transcribed by RNA polymerase I of Leishmania
cells. Interestingly, gene regulation, in Trypanosomatidae,
occurs predominantly after transcription through intergenic
untranslated regions (UTRs) [25]. Therefore, suitable UTRs
should be chosen. The origins of UTRs of pLEXSY-hyg2
expression vector are as follows: UTR1, 5  nontranslated
region of aprt gene of Leishmania with splice acceptor site
for target gene; UTR2, 1.4kb intergenic region from cam
operon of Leishmania with polyA site for target gene and
splice acceptor site for marker gene; UTR3, 5  UTR of dhfr-ts
gene of Leishmania with polyA site for marker gene. Results
of this study are also in agreement with earlier observations
that Leishmania species are able to produce heterologous
proteins.
By using native human signal sequence, Breitling et al.
[14] could obtain the clone with the maximum expression-
produced recombinant erythropoietin at approximately
30mg/L of suspension culture.
In this study, the ﬁnal yield of the puriﬁed rFVII was
estimated to be about 1μg/mL of culture medium. This yield
was comparable to that of rFVII-producing mammalian
and insect cell lines [10, 26, 27]. Furthermore, it has been
demonstrated that Leishmania tarentolae is able to produce
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Figure 7: Estimation of the yield of functional rFVII (rFVIIa) by
one-stage clotting assay (PT-based assay for FVII). Standard curve
of diﬀerent dilutions of unicalibrator was made. Also, clotting times
of dilutions of (1/1), (1/2), (1/5), (1/10) of dialyzed rFVII were
recorded. The clotting times of dilutions of dialyzed rFVII were
33, 42, 44, and 48 (s), respectively. The black line mark the (1/1)
dilution of dialyzed rFVII activity at the point of intersection of the
standard curve through this the yield of functional rFVII (rFVIIa)
was estimated 9% of Unicalibrator with 100% FVIIa level. The
clotting time of the negative control sample (without FVII) was 60
(s).
mammalian-like biantennary N-glycans [28]. So, according
to the estimated molecular weight of rFVII produced by
Leishmania cells and its comparison with carefully selected
positive control of FVII (FVIIa, US Biological), it is thought
that N-glycosylation proﬁle and probably the protein folding
of this product are similar to those in mammalian cells [29].
Before puriﬁcation of rFVIIa, electrophoretic and west-
ern blot analysis indicated that it consisted of a single band
withanestimatedmolecularweightof55kDaonSDS-PAGE.
It indicates that rFVII has been synthesized as a single-
chain form and then cleaved to the biologically active form
during protein puriﬁcation. Western blot analysis indicated
that the resultant active form is composed of light and heavy
chains with a molecular weight of ∼20KDa and ∼30KDa,
respectively [30].
The results of PT assay showed a reduction in clotting
time of about 30 seconds with the puriﬁed rFVII. As demon-
strated by comparing clotting time of the dialyzed rFVII
with standard curve, the yield of functional rFVII (rFVIIa)
was estimated 9%. The speciﬁc ﬁndings with this product
may be related to its posttranslational modiﬁcation like γ-
carboxylation. And it should be noted that considerably
more investigations are required in order to determine
posttranslational γ-carboxylation of glutamic acid residues
in Gla domain of this product in Leishmania cells.
In conclusion, this study has demonstrated for the ﬁrst
time that Leishmania cells can be used as a powerful host
for production of recombinant human FVII. The mainJournal of Biomedicine and Biotechnology 7
advantages of this expression system are its easy handling
like E. coli and yeast expression systems, proper protein
folding, posttranslation modiﬁcation and cultivation in low-
cost media such as LB.
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